India’s indigenously-developed mRNA vaccine has received regulatory nod for Phase II and III clinical trials, said an official statement on Tuesday.

This is the second mRNA vaccine to reach advanced trial stage, after Moderna’s mRNA vaccine, which is already in use in the US and several other countries.

The vaccine developed by Pune-based Gennova Biopharmaceuticals was approved for further trials by the Drugs Controller General of India (DCGI), as the apex regulatory body found the interim clinical data from Phase I trials submitted by the firm satisfactory.
https://www.thehindubusinessline.com/companies/gennovas-mrna-vax-ge...